Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone palmitate in schizophrenia
NCT00074477Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Oct 2003
- Modality
- Metabolically Activated Prodrugs
01
Overview
Phase 2, randomised, double-blind trial of paliperidone palmitate in schizophrenia (3 arms), sponsored by Johnson & Johnson. Primary endpoint: Positive and Negative Symptom Scale for Schizophrenia at 64 days. Started Oct 2003; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00074477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00074477.